32.06

2.13% 0.67

After Hours: 32.06

Rigel Pharmaceuticals (RIGL)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rigel Pharmaceuticals stock is traded at $32.06, with a volume of 382.23K. It is up +2.13% in the last 24 hours and up +23.55% over the past month. Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Previous Close:

$31.39

Open:

$31.56

24h Volume:

382.23K

Relative Volume:

1.07

Market Cap:

$592.47M

Revenue:

$294.28M

Net Income/Loss:

$367.02M

P/E Ratio:

1.6953

EPS:

18.9115

Net Cash Flow:

$75.66M

1W Performance:

+7.84%

1M Performance:

+23.55%

6M Performance:

+14.05%

1Y Performance:

+88.15%

1-Day Range:

$31.56

$32.24

1-Week Range:

$28.78

$32.24

52-Week Range:

$16.05

$52.24

Rigel Pharmaceuticals Stock (RIGL) Company Profile

Name

Rigel Pharmaceuticals

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

650-624-1100

Address

611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA

Employee

174

Twitter

@rigelpharma

Next Earnings Date

2026-03-03

Latest SEC Filings

RIGL's Discussions on Twitter

Compare RIGL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RIGL Rigel Pharmaceuticals	32.06	580.09M	294.28M	367.02M	75.66M	18.91
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-25	Upgrade	Jefferies	Hold → Buy
Apr-03-23	Resumed	Piper Sandler	Neutral
Jun-09-22	Downgrade	Citigroup	Buy → Neutral
Jun-08-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-08-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-23-22	Initiated	B. Riley Securities	Neutral
Nov-09-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-15-19	Resumed	Cantor Fitzgerald	Overweight
Sep-26-19	Resumed	JP Morgan	Overweight
Mar-01-19	Reiterated	Cantor Fitzgerald	Overweight
Aug-27-18	Initiated	Citigroup	Buy
May-02-18	Reiterated	Cantor Fitzgerald	Overweight
Dec-21-17	Resumed	Piper Jaffray	Overweight
Dec-15-17	Initiated	Cantor Fitzgerald	Overweight
Nov-06-17	Resumed	H.C. Wainwright	Buy
Mar-09-17	Reiterated	H.C. Wainwright	Buy
Aug-31-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Reiterated	Piper Jaffray	Overweight
Jul-13-16	Initiated	H.C. Wainwright	Buy
Jun-13-16	Initiated	Piper Jaffray	Overweight
Apr-22-16	Upgrade	JP Morgan	Neutral → Overweight
Apr-08-13	Reiterated	Stifel	Buy
Nov-29-12	Initiated	UBS	Neutral
Nov-06-12	Reiterated	Oppenheimer	Outperform
Mar-26-12	Initiated	Canaccord Genuity	Hold
Dec-10-10	Downgrade	MP Advisors	Outperform → Market Perform

View All

Rigel Pharmaceuticals Stock (RIGL) Latest News

Apr 14, 2026

(RIGL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Apr 14, 2026

Apr 13, 2026

RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill

Apr 13, 2026

Apr 12, 2026

Why Rigel Pharmaceuticals Lost Big in December - AOL.com

Apr 12, 2026

Ritholtz Wealth Management Boosts Rigel Pharmaceuticals Holdings - National Today

Apr 12, 2026

Apr 10, 2026

Why VAALCO Energy, Rigel Pharmaceuticals, and Companhia Siderurgica Nacional Are Today's 3 Best Stoc - Yahoo

Apr 10, 2026

Apr 09, 2026

Rigel's 2026 Earnings Goal Sets Up Discounted Stock for Potential Clash With Analysts' 82% Price Projections - Bitget

Apr 09, 2026

Rigel Pharmaceuticals Was Easy To DismissNow It's Hard To Ignore (Rating Upgrade) - Seeking Alpha

Apr 09, 2026

Apr 08, 2026

Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance - MSN

Apr 08, 2026

Rigel Attracts Big Money as Charts Signal Caution - Bitget

Apr 08, 2026

Apr 07, 2026

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - StreetInsider

Apr 07, 2026

Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance Singapore

Apr 07, 2026

Aug Levels: What is the Moat Score of Rigel Pharmaceuticals IncWeekly Market Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn

Apr 07, 2026

Rigel Pharmaceuticals Grants Inducement RSUs to New Hires - National Today

Apr 07, 2026

Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛

Apr 07, 2026

Apr 06, 2026

Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Apr 06, 2026

Rigel Pharmaceuticals Inc (FRA:RI2) Stock Price & 30 Year Financial Data - GuruFocus

Apr 06, 2026

Apr 04, 2026

RIGL PE Ratio & Valuation, Is RIGL Overvalued - Intellectia AI

Apr 04, 2026

Apr 03, 2026